Compared to other state-of-the-art models such as AlphaFold3, mamp-ml can predict these outcomes with higher confidence, even when a solved structure is not available. We anticipate users can now screen for immunogenic outcomes of receptor-ligand variants before spending time and $$ in the lab.
